Ga-68-Edotreotide Positron Emission Tomography/Computed Tomography Somatostatin Receptors Tumor Volume Predicts Outcome in Patients With Primary Gastroenteropancreatic Neuroendocrine Tumors

Gallicchio, Rosj; Giordano, A; Milella, Mariarita; Storto, Rebecca; Pellegrino, Teresa; Nardelli, Anna; Nappi, Antonio; Tarricone, Luigia; Storto, Giovanni

doi:10.1177/10732748231152328

Cited by 3 publications

(1 citation statement)

References 34 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Somatostatin receptors (SSTR) type 2, 3 and 5 in has been demonstrated in various studies in DTC cells but also in normal thyroid tissue and benign thyroid diseases [67][68][69][70][71]. Radiolabeled somatostatin analogs, such as octreotide and lanreotide marked with 68Ga-DOTA, have discovered a pretty large use in PET/CT SSTR imaging in last years, especially in neuro endocrine tumor (NET) imaging [72][73][74][75][76]. However, the role of SSTR tracers in RAIR-DTC remains unclear.…”

Section: Future Diagnostic and Therapeutic Perspectivesmentioning

confidence: 99%

Current Advances in Radioactive Iodine Refractory Differentiated Thyroid Cancer

Volpe,

Nappi,

Zampella

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Differentiated thyroid cancer (DTC) patients have an outstanding overall long-term survival rate, certain subsets of DTC patients have a very high likelihood of disease recurrence. Radioactive iodine therapy is a cornerstone in DTC management, but sometimes it became useless when cancer cells develop refractoriness. Radioactive Iodine Refractory DTC (RAIR-DTC) is a condition defined by ATA 2015 guidelines when DTC cannot concentrate RAI ab initio or loses RAI uptake ability after the initial therapy. RAIR condition implies that RAI cannot reveal new met-astatic foci, so RAIR-DTC metabolic imaging needs new tracers. 18F-FDG PET/CT has been widely used, it has a demonstrated prognostic value, but 18F-FDG DTC avidity may remain low. FA-Pi, PSMA, SSTR tracers have been proposed as theragnostic agents in experimental settings and Arg-Gly-Asp (RGD) peptides in diagnostic trial field. Multi-targeted tyrosine kinase inhibitors are relatively new drugs approved in RAIR-DTC therapy. Despite the promising targeted setting, they relate to frequent adverse event onset. Sorafenib and trametinib have been included in re-differentiation protocols aimed to re-induce RAI accumulation in DTC cells. Results appeared promising, despite not excellent. Conclusions: RAIR-DTC yet represent a challenging nosological entity. There are still controversies on RAIR-DTC definition and post-RAI therapy evaluation with post-therapy whole body scan (PT-WBS) is the only validated criterion of response. The recent introduction of multiple diagnostic and therapeutic agents oblige physicians to pursue a multidisciplinary approach aiming to correct drug introduction and timing choice.

show abstract

Section: Future Diagnostic and Therapeutic Perspectivesmentioning

confidence: 99%

Current Advances in Radioactive Iodine Refractory Differentiated Thyroid Cancer

Volpe,

Nappi,

Zampella

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Accelerator production, radiochemical separation and nanoradiopharmaceutical formulation using 69Ge: A next generation PET probe

Patra,

Ghosh,

Singh

et al. 2024

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Volpe,

Nappi,

Zampella

et al. 2024

Current Oncology

View full text Add to dashboard Cite

Background: Differentiated thyroid cancer (DTC) patients have an outstanding overall long-term survival rate, and certain subsets of DTC patients have a very high likelihood of disease recurrence. Radioactive iodine (RAI) therapy is a cornerstone in DTC management, but cancer cells can eventually develop resistance to RAI. Radioactive iodine-refractory DTC (RAIR-DTC) is a condition defined by ATA 2015 guidelines when DTC cannot concentrate RAI ab initio or loses RAI uptake ability after the initial therapy. The RAIR condition implies that RAI cannot reveal new met-astatic foci, so RAIR-DTC metabolic imaging needs new tracers. 18F-FDG PET/CT has been widely used and has demonstrated prognostic value, but 18F-FDG DTC avidity may remain low. Fibroblast activation protein inhibitors (FA-Pi)s, prostatic-specific membrane antigen (PSMA), and somatostatin receptor (SSTR) tracers have been proposed as theragnostic agents in experimental settings and Arg-Gly-Asp (RGD) peptides in the diagnostic trial field. Multi-targeted tyrosine kinase inhibitors are relatively new drugs approved in RAIR-DTC therapy. Despite the promising targeted setting, they relate to frequent adverse-event onset. Sorafenib and trametinib have been included in re-differentiation protocols aimed at re-inducing RAI accumulation in DTC cells. Results appear promising, but not excellent. Conclusions: RAIR-DTC remains a challenging nosological entity. There are still controversies on RAIR-DTC definition and post-RAI therapy evaluation, with post-therapy whole-body scan (PT-WBS) the only validated criterion of response. The recent introduction of multiple diagnostic and therapeutic agents obliges physicians to pursue a multidisciplinary approach aiming to correct drug introduction and timing choice.

show abstract

Ga-68-Edotreotide Positron Emission Tomography/Computed Tomography Somatostatin Receptors Tumor Volume Predicts Outcome in Patients With Primary Gastroenteropancreatic Neuroendocrine Tumors

Cited by 3 publications

References 34 publications

Current Advances in Radioactive Iodine Refractory Differentiated Thyroid Cancer

Current Advances in Radioactive Iodine Refractory Differentiated Thyroid Cancer

Accelerator production, radiochemical separation and nanoradiopharmaceutical formulation using 69Ge: A next generation PET probe

Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Contact Info

Product

Resources

About